A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4126-4126
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4142-4142
2010 ◽
Vol 28
(15_suppl)
◽
pp. e14511-e14511
◽